Mustang Bio, Inc. MBIO
Set alert
0.40 USD +0.01 +1.94%
At close · Oct 30
0.39 -0.01 -2.00%
After hours · Oct 30, 4:00 PM ET
0.39 Day range 0.427
0.36 52-week range 1.46
- YTD
- -59.22%
- 1 year
- -72.60%
- Open
- 0.3932
- Prev close
- 0.3925
- Mkt cap
- 3.03M
- Vol
- 48.29K
- Avg vol
- 30.65K
- EPS
- -0.44
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.39
- High
- 0.427
- Forward P/E
- -0.47
- Beta
- 0.00
- Short ratio
- 0.22
- Inst. own
- 5.72%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 0.22622
- 200-d avg
- 0.369385
- 1y target
- 0.00
2Y chart
Events in this range
- Nov 8, 2024Earnings: -0.04; estimate -0.13; surprise 69.23%
- Jan 16, 2025Split: 1 for 50
Signals (79)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | Oct 27, 2026 | 4 days ago |
| RSI: Oversold | Oct 22, 2026 | 1 week ago |
| RSI: Oversold | Oct 8, 2026 | 3 weeks ago |
| MACD: Sell Signal | Sep 30, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 18, 2026 | 1 month ago |
| RSI: Oversold | Sep 17, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 10, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 3, 2026 | 1 month ago |
| MACD: Sell Signal | Aug 25, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 5, 2026 | 2 months ago |
| SMA: Bearish | Jul 13, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 13, 2026 | 3 months ago |
| SMA: Bullish | Jul 9, 2026 | 3 months ago |
| MACD: Buy Signal | Jul 9, 2026 | 3 months ago |
| SMA: Bearish | Jul 8, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 8, 2026 | 3 months ago |
| MACD: Buy Signal | Jul 6, 2026 | 3 months ago |
| SMA: Bullish | Jun 30, 2026 | 4 months ago |
| SMA: Bearish | Jun 18, 2026 | 4 months ago |
| MACD: Sell Signal | Jun 18, 2026 | 4 months ago |
| SMA: Bullish | Jun 17, 2026 | 4 months ago |
| SMA: Bearish | Jun 16, 2026 | 4 months ago |
| SMA: Bullish | Jun 9, 2026 | 4 months ago |
| SMA: Bearish | Jun 4, 2026 | 4 months ago |
| SMA: Bullish | Jun 1, 2026 | 5 months ago |
| MACD: Buy Signal | May 27, 2026 | 5 months ago |
| RSI: Oversold | May 14, 2026 | 5 months ago |
| MACD: Sell Signal | May 11, 2026 | 5 months ago |
| MACD: Buy Signal | Apr 14, 2026 | 6 months ago |
| RSI: Oversold | Mar 26, 2026 | 7 months ago |
| MACD: Sell Signal | Mar 16, 2026 | 7 months ago |
| SMA: Bearish | Mar 12, 2026 | 7 months ago |
| SMA: Bullish | Mar 10, 2026 | 7 months ago |
| MACD: Buy Signal | Mar 10, 2026 | 7 months ago |
| MACD: Sell Signal | Mar 9, 2026 | 7 months ago |
| SMA: Bearish | Mar 2, 2026 | 8 months ago |
| SMA: Bullish | Feb 24, 2026 | 8 months ago |
| MACD: Buy Signal | Feb 12, 2026 | 8 months ago |
| RSI: Oversold | Feb 3, 2026 | 9 months ago |
| MACD: Sell Signal | Jan 28, 2026 | 9 months ago |
| MACD: Buy Signal | Jan 22, 2026 | 9 months ago |
| MACD: Sell Signal | Jan 21, 2026 | 9 months ago |
| MACD: Buy Signal | Jan 5, 2026 | 9 months ago |
| MACD: Sell Signal | Dec 16, 2025 | 10 months ago |
| MACD: Buy Signal | Nov 24, 2025 | 11 months ago |
| RSI: Oversold | Nov 17, 2025 | 11 months ago |
| SMA: Bearish | Oct 16, 2025 | 1 year ago |
| MACD: Sell Signal | Oct 16, 2025 | 1 year ago |
| SMA: Bullish | Oct 13, 2025 | 1 year ago |
| SMA: Bearish | Oct 10, 2025 | 1 year ago |
| SMA: Bullish | Oct 7, 2025 | 1 year ago |
| MACD: Buy Signal | Sep 11, 2025 | 1 year ago |
| MACD: Sell Signal | Aug 20, 2025 | 1 year ago |
| SMA: Bearish | Aug 18, 2025 | 1 year ago |
| MACD: Buy Signal | Aug 14, 2025 | 1 year ago |
| SMA: Bullish | Aug 8, 2025 | 1 year ago |
| SMA: Bearish | Jul 30, 2025 | 1 year ago |
| MACD: Sell Signal | Jul 21, 2025 | 1 year ago |
| RSI: Overbought | Jul 7, 2025 | 1 year ago |
| SMA: Bullish | Jul 1, 2025 | 1 year ago |
| MACD: Buy Signal | Jul 1, 2025 | 1 year ago |
| RSI: Overbought | Jul 1, 2025 | 1 year ago |
| RSI: Oversold | Jun 17, 2025 | 1 year ago |
| SMA: Bearish | Jun 13, 2025 | 1 year ago |
| MACD: Sell Signal | Jun 13, 2025 | 1 year ago |
| SMA: Bullish | Jun 9, 2025 | 1 year ago |
| SMA: Bullish | May 27, 2025 | 1 year ago |
| SMA: Bearish | May 23, 2025 | 1 year ago |
| SMA: Bullish | May 22, 2025 | 1 year ago |
| RSI: Oversold | Apr 3, 2025 | 1 year ago |
| RSI: Oversold | Feb 28, 2025 | 1 year ago |
| RSI: Oversold | Feb 25, 2025 | 1 year ago |
| MACD: Buy Signal | Feb 12, 2025 | 1 year ago |
| RSI: Oversold | Feb 5, 2025 | 1 year ago |
| RSI: Oversold | Jan 27, 2025 | 1 year ago |
| RSI: Oversold | Jan 21, 2025 | 1 year ago |
| MACD: Sell Signal | Jan 15, 2025 | 1 year ago |
| RSI: Overbought | Jan 10, 2025 | 1 year ago |
| RSI: Oversold | Dec 18, 2024 | 1 year ago |
Key statistics
- Market cap
- 8.14M
- Enterprise value
- 5.48M
- Trailing P/E
- 0.00
- Forward P/E
- -0.47
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- EPS (TTM)
- -1.33
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -9.37M
- Total cash
- 3.52M
- Total debt
- 983.00K
- Return on equity
- 0.00%
- Shares outstanding
- 48.77M
- Short % of float
- 0.54%
- 50-day average
- 0.22622
- 200-day average
- 0.369385
Analyst view
Consensus: none
Price target (mean) 0.00
Next earnings
Consensus EPS estimate -0.16.
Financials — quick view
MBIO Revenue — quarterly 0
MBIO Net income — quarterly -1.07M
MBIO EPS — quarterly -0.16
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 8, 2024 | Sep 1, 2024 | -0.13 | -0.04 | +0.09 | +69.23% |
| Aug 13, 2024 | Jun 1, 2024 | -0.14 | -0.24 | -0.10 | -71.43% |
| May 15, 2024 | Mar 1, 2024 | 0.00 | -0.46 | — | — |
| Mar 11, 2024 | Dec 1, 2023 | -1.68 | -0.71 | +0.97 | +57.74% |
| Nov 14, 2023 | Sep 1, 2023 | -1.88 | -1.23 | +0.65 | +34.57% |
| Aug 14, 2023 | Jun 1, 2023 | -2.07 | -2.00 | +0.07 | +3.38% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| May 16, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| May 13, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Aug 24, 2023 | Cantor Fitzgerald | reit | Overweight | Overweight |
| Aug 16, 2023 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 15, 2023 | BTIG | main | Buy | Buy |
| Aug 15, 2023 | HC Wainwright & Co. | reit | Buy | Buy |
About Mustang Bio, Inc.
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-117 and MB-217, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. The company also develops MB-106 CAR T cell program for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-101 CAR T cell program for glioblastoma; MB-108, a next-generation oncolytic herpes simplex virus. It has license agreements with Nationwide Children's Hospital, CSL Behring; Mayo Clinic; Leiden University Medical Centre; SIRION Biotech GmbH. The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts. Avenue Mustang Bio, Inc. is a subsidiary of Fortress Biotech, Inc.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- mustangbio.com
News
- MindBio Completes Manufacture and Delivery of First Prototype Edge AI Intoxication and Fatigue Detection Kiosks
- 12 Health Care Stocks Moving In Friday's After-Market Session
- MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) Harnesses Key AI, Voice Analysis to Offer Impairment Solution
- IBN Announces Latest Episode of The TechMediaWire Podcast featuring Justin Hanka, CEO of MindBio Therapeutics Corp.
- MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) Leveraging AI, Voice Analysis to Develop Intoxication Detection
- MindBio Announces Closing of Private Placement
- MindBio Announces Upsize to Private Placement up to $1.5 Million
- Critical Contrast: Mustang Bio (NASDAQ:MBIO) & AstraZeneca (NASDAQ:AZN)
- MindBio Announces Private Placement to Raise up to $650,000
- MindBio Advances Large-Scale Deployment of Voice Intoxication Detection Through Integrated Edge AI Hardware-Software Platform
Your note
Sign in to keep a note on MBIO — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CHILL ADAM J | Director | Stock Award(Grant) | Jul 4, 2023 | 19,170 |
| FORTRESS BIOTECH, INC. | Beneficial Owner of more than 10% of a Class of Security | Stock Award(Grant) | Jun 26, 2024 | 2,502,990 |
| HERSKOWITZ NEIL | Director | Stock Award(Grant) | Jul 4, 2023 | 19,703 |
| LITCHMAN MANUEL | Chief Executive Officer | Stock Award(Grant) | Apr 23, 2023 | 111,079 |
| ROSENWALD LINDSAY A | Director | Stock Award(Grant) | Jul 4, 2023 | 60,525 |
| WEISS MICHAEL S | Director | Stock Award(Grant) | Jul 4, 2023 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Geode Capital Management, LLC | 0.52% | 245,486 | 40.26K | Sep 29, 2024 |
| Citadel Advisors Llc | 0.24% | 112,773 | 18.49K | Sep 29, 2024 |
| Koss-olinger Consulting, Llc | 0.21% | 98,366 | 16.13K | Sep 29, 2024 |
| Blackrock Inc. | 0.18% | 83,337 | 13.67K | Sep 29, 2024 |
| Vanguard Group Inc | 0.16% | 75,394 | 12.36K | Sep 29, 2024 |
| Susquehanna International Group, LLP | 0.14% | 66,304 | 10.87K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 0.40% | 186,341 | 30.56K | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.16% | 73,419 | 12.04K | Sep 29, 2024 |
| Fidelity Total Market Index Fund | 0.11% | 53,860 | 8.83K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.09% | 43,574 | 7.15K | Oct 30, 2024 |
| Fidelity Enhanced Small Cap ETF | 0.02% | 7,462 | 1.22K | Oct 30, 2024 |
| Delaware Group Equity Fds IV-Delaware Healthcare Fund | 0.02% | 8,000 | 1.31K | Sep 29, 2024 |